Ibritumomab tiuxetan
Top View
- Antibody-Drug Conjugates: Intellectual Property Considerations
- Bladder Cancer
- Zevalin, INN-Ibritumomab Tiuxetan
- Y90 Ibritumomab Tiuxetan and I131 Tositumomab
- Zevalin) Regimen: Results from a Zevalin Imaging Registry
- Novel Antibodies in the Treatment of Non-Hodgkin's Lymphoma
- Radioimmunoconjugates
- Pcn43 the Cost of Treating Grade 3/4 Adverse Events
- Ibritumomab Tiuxetan (Interim Monograph)
- The Evolution of Antibodies Into Versatile Tumor-Targeting Agents
- Brentuximab Vedotin and Diffuse Large B-Cell Lymphoma
- Biologic & Other Novel Agents
- 11510B ZEV Patient Brochure R25v4 FIN.Indd
- From Current Clinical Success to Future Industrial Breakthrough?
- FDA Drug Label
- (90Y)-Ibritumomab Tiuxetan in Stem Cell Transplantation for Non-Hodgkin’S Lymphoma
- Oncology Therapy for the Generalist
- Toxicology Section of the NCI/CIP IND for 89Zr-Panitumumab. This